Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(07): 417-423
DOI: 10.1055/s-0035-1565095
Article
© Georg Thieme Verlag KG Stuttgart · New York

Serum miR-21 may be a Potential Diagnostic Biomarker for Diabetic Nephropathy

J. Wang   *
1   Department of Endocrinology, Gansu Provincial People’s Hospital, Donggang West Road, Lanzhou, PR China
,
L. Duan   *
2   Department of Gynecology and Obstetrics, Gansu Provincial People’s Hospital, Donggang West Road, Lanzhou, PR China
,
L. Tian
1   Department of Endocrinology, Gansu Provincial People’s Hospital, Donggang West Road, Lanzhou, PR China
,
J. Liu
1   Department of Endocrinology, Gansu Provincial People’s Hospital, Donggang West Road, Lanzhou, PR China
,
S. Wang
3   Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, Tianjin, China
,
Y. Gao
4   Metabolic Disease Center, School of Traditional Chinese medical, Capital Medical University, Beijing, China
,
J. Yang
5   Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
› Author Affiliations
Further Information

Publication History

received 06 September 2015
first decision 07 October 2015

accepted 12 October 2015

Publication Date:
17 November 2015 (online)

Also available at
   Permissions and Reprints

Abstract

MiRNAs play important roles in initiation and progress of many pathologic processes. MiR-21 was closely associated with diabetic nephropathy (DN). However, whether serum miR-21 was as a potential diagnostic biomarker for DN and the relationship between serum miR-21 and tissue miR-21 remained unclear. In this study, real-time RT-PCR, cell transfection, luciferase reporter gene assays, western blot and confocal microscope were used, respectively. Here, we found that serum and renal tissue miR-21 was significantly elevated with the progress of DN. Moreover, luciferase reporter gene assays showed that smad7 was a validated miR-21 target, cell transfection showed that miR-21 overexpression downregulated target smad7 expression. Interestingly, serum miR-21 was significantly consistent with the alterations of tissue miR-21 with the development of DN. In addition, serum miR-21 was also positively correlated with GBM, GA, ACR and CCF, while negatively correlated with Ccr. Importantly, antagomiR-21 not only alleviated GBM, GA, ACR and CCF, but also ameliorated Ccr by increasing target smad7. In conclusion, our data demonstrated that serum miR-21 was closely associated with renal structure and function, and serum miR-21 may be regarded as a potential diagnostic biomarker of DN.

Key words

serum miR-21 - diabetic nephropathy - structure and function - diagnostic biomarker

* Jinyang Wang and Lijun Duan contributed equally to this study.


 

  • References

  • 1 Nishi S, Ueno M, Hisaki S et al. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc 2000; 33: 65-73 DOI: 10.1007/s007950000012.
    CrossrefPubMedGoogle Scholar
  • 2 Zhong H, Liu F, Fu P et al. A comparison of clinical characteristics and survival between diabetic nephropathy patients and non-diabetic nephropathy patients undergoing peritoneal dialysis. Sichuan Da Xue Xue Bao Yi Xue Ban 2012; 43: 442-446
    PubMedGoogle Scholar
  • 3 Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant 1998; 13 (Suppl. 08) 6-10
    PubMedGoogle Scholar
  • 4 Ito T, Tanimoto M, Yamada K et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006; 11: 29-35 DOI: 10.1111/j.1440-1797.2006.00543.x.
    CrossrefPubMedGoogle Scholar
  • 5 Perron MP, Provost P. Protein interactions and complexes in human microRNA biogenesis and function. Frontiers in bioscience: a journal and virtual library 2008; 13: 2537-2547
    CrossrefPubMedGoogle Scholar
  • 6 Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93: 583-593 DOI: cvr300. [pii]10.1093/cvr/cvr300
    CrossrefPubMedGoogle Scholar
  • 7 He A, Zhu L, Gupta N et al. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-2794 DOI: me.2007-0167. [pii]10.1210/me.2007-0167
    CrossrefPubMedGoogle Scholar
  • 8 Qin W, Chung AC, Huang XR et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011; 22: 1462-1474 DOI: ASN.2010121308. [pii]10.1681/ASN.2010121308
    CrossrefPubMedGoogle Scholar
  • 9 Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008; 22: 4126-4135 DOI: fj.08-112326. [pii]10.1096/fj.08-112326
    CrossrefPubMedGoogle Scholar
  • 10 Zhang Z, Luo X, Ding S et al. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett 2012; 586: 20-26 DOI: S0014-5793(11)00571-0. [pii]10.1016/j.febslet.2011.07.042
    CrossrefPubMedGoogle Scholar
  • 11 Caporali A, Meloni M, Vollenkle C et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011; 123: 282-291 DOI: CIRCULATIONAHA.110.952325. [pii]10.1161/CIRCULATIONAHA.110.952325
    CrossrefPubMedGoogle Scholar
  • 12 Chung AC, Huang XR, Meng X et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. Journal of the American Society of Nephrology: JASN 2010; 21: 1317-1325 DOI: 10.1681/ASN.2010020134.
    CrossrefPubMedGoogle Scholar
  • 13 Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. Journal of cellular and molecular medicine 2009; 13: 39-53 DOI: 10.1111/j.1582-4934.2008.00556.x.
    PubMedGoogle Scholar
  • 14 Zarjou A, Yang S, Abraham E et al. Identification of a microRNA signature in renal fibrosis: role of miR-21. American journal of physiology Renal physiology 2011; 301: F793-F801 DOI: 10.1152/ajprenal.00273.2011.
    CrossrefPubMedGoogle Scholar
  • 15 Fiorentino L, Cavalera M, Mavilio M et al. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta diabetologica 2013; 50: 965-969 DOI: 10.1007/s00592-013-0492-8.
    CrossrefPubMedGoogle Scholar
  • 16 Lai JY, Luo J, O’Connor C et al. MicroRNA-21 in glomerular injury. Journal of the American Society of Nephrology: JASN 2015; 26: 805-816 DOI: 10.1681/ASN.2013121274.
    CrossrefPubMedGoogle Scholar
  • 17 Dey N, Das F, Mariappan MM et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. The Journal of biological chemistry 2011; 286: 25586-25603 DOI: 10.1074/jbc.M110.208066.
    CrossrefPubMedGoogle Scholar
  • 18 Chau BN, Xin C, Hartner J et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Science translational medicine 2012; 4 121ra118 DOI: 10.1126/scitranslmed.3003205.
    PubMedGoogle Scholar
  • 19 Zhang Z, Peng H, Chen J et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS letters 2009; 583: 2009-2014 DOI: 10.1016/j.febslet.2009.05.021.
    CrossrefPubMedGoogle Scholar
  • 20 Zhong X, Chung AC, Chen HY et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56: 663-674 DOI: 10.1007/s00125-012-2804-x.
    CrossrefPubMedGoogle Scholar
  • 21 Glowacki F, Savary G, Gnemmi V et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 2013; 8: e58014 DOI: 10.1371/journal.pone.0058014PONE-D-12-31316. [pii]
    CrossrefPubMedGoogle Scholar
  • 22 Wang J, Gao Y, Ma M et al. Effect of miR-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in kk-ay Diabetic Nephropathy Mice. Cell Biochem Biophys 2013; DOI: 10.1007/s12013-013-9539-2.
    PubMedGoogle Scholar
  • 23 Wang JY, Gao YB, Zhang N et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Molecular and cellular endocrinology 2014; 392: 163-172 DOI: 10.1016/j.mce.2014.05.018.
    CrossrefPubMedGoogle Scholar
  • 24 Krutzfeldt J, Kuwajima S, Braich R et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007; 35: 2885-2892 DOI: gkm024. [pii]10.1093/nar/gkm024
    CrossrefPubMedGoogle Scholar
  • 25 Yokozawa T, Nakagawa T, Wakaki K et al. Animal model of diabetic nephropathy. Exp Toxicol Pathol 2001; 53: 359-363
    CrossrefPubMedGoogle Scholar
  • 26 Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373
    CrossrefPubMedGoogle Scholar
  • 27 Ka SM, Yeh YC, Huang XR et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012; 55: 509-519 DOI: 10.1007/s00125-011-2364-5.
    CrossrefPubMedGoogle Scholar
  • 28 Chung AC, Dong Y, Yang W et al. Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Molecular therapy: the journal of the American Society of Gene Therapy 2013; 21: 388-398 DOI: 10.1038/mt.2012.251.
    CrossrefPubMedGoogle Scholar
  • 29 Meister G. miRNAs get an early start on translational silencing. Cell 2007; 131: 25-28 DOI: S0092-8674(07)01209-3. [pii]10.1016/j.cell.2007.09.021
    CrossrefPubMedGoogle Scholar
  • 30 El-Hefnawy T, Raja S, Kelly L et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2004; 50: 564-573 DOI: 10.1373/clinchem.2003.028506clinchem.2003.028506. [pii]
    CrossrefPubMedGoogle Scholar
  • 31 Wang HJ, Zhang PJ, Chen WJ et al. Characterization and Identification of novel serum microRNAs in sepsis patients with different outcomes. Shock 2013; 39: 480-487 DOI: 10.1097/SHK.0b013e3182940cb8.
    CrossrefPubMedGoogle Scholar
  • 32 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 DOI: cr2008282. [pii]10.1038/cr.2008.282
    CrossrefPubMedGoogle Scholar
  • 33 Sisco KL. Is RNA in serum bound to nucleoprotein complexes?. Clin Chem 2001; 47: 1744-1745
    PubMedGoogle Scholar
  • 34 Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002; 48: 1647-1653
    PubMedGoogle Scholar
  • 35 Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678
    CrossrefPubMedGoogle Scholar
  • 36 Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152 DOI: jc.2007-1817. [pii]10.1210/jc.2007-1817
    CrossrefPubMedGoogle Scholar
  • 37 Osterby R. Morphometric studies of the peripheral glomerular basement membrane. II. Topography of the initial lesions. Diabetologia 1973; 9: 108-114
    CrossrefPubMedGoogle Scholar
  • 38 Liu G, Friggeri A, Yang Y et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-1597 DOI: jem.20100035. [pii]10.1084/jem.20100035
    CrossrefPubMedGoogle Scholar
  • 39 Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984 DOI: nature07511. [pii]10.1038/nature07511
    CrossrefPubMedGoogle Scholar